Background: Recent case studies and media outlets have hypothesised an effect of SARS-CoV-2 infection and immunisation on the development or progression of neurodegenerative diseases such as Alzheimer's disease or sporadic Creutzfeldt-Jakob disease (sCJD).
Objectives: This study aims to identify potential associations of SARS-CoV-2 infections and SARS-CoV-2 immunisation with sCJD incidence, disease duration, and age of onset.
Method: We used data from a prospective sCJD surveillance study in Germany (2016-2022) and publicly available datasets of SARS-CoV-2 cases and vaccination numbers in Germany for the years 2020-2022. Associations of SARS-CoV-2 incidence and immunisation rates with sCJD incidence were assessed by comparing quarterly and annual cumulative sCJD incidences in the periods before (2016-2019) and during the pandemic (2020-2022).
Results: We could not identify any time-related effect of SARS-CoV-2 incidence or immunisation rate on the sCJD incidence. Moreover, we did not find any sCJD incidence alterations before and during the SARS-CoV-2 pandemic on a federal or state level. The overall sCJD incidence was within expected ranges in the years 2020-2022. There were no changes in age of onset and clinical disease duration in these years.
Conclusions: We found no evidence supporting a short-term effect of the pandemic on sCJD incidence. However, considering the extended pre-clinical phase of sCJD, continued surveillance is needed to identify potential future incidence alterations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000535112 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mood Alterations in the Prodromal Phase of Sporadic Creutzfeldt-Jakob Disease.
JAMA Neurol
December 2024
Department of Neurology, Medical University of Vienna, Vienna, Austria.
Importance: Sporadic Creutzfeldt-Jakob disease (sCJD) is a rare, rapidly progressive and fatal neurodegenerative disease. Definite sCJD diagnosis can only be made post mortem, and little is known about the prodromal phase of the disease.
Objective: To compare drug prescription patterns before the clinical onset of sCJD between patients and matched controls for exploration of potential risk factors and to assess correlations between drug exposure and sCJD survival.
Interpretable deep learning survival predictions in sporadic Creutzfeldt-Jakob disease.
J Neurol
December 2024
The UK National CJD Research and Surveillance Unit, Centre for Clinical Brain Sciences, Chancellor's Building, University of Edinburgh, Edinburgh, EH16 4TG, UK.
Background: Sporadic Creutzfeldt-Jakob disease (sCJD) is a rapidly progressive and fatal prion disease with significant public health implications. Survival is heterogenous, posing challenges for prognostication and care planning. We developed a survival model using diagnostic data from comprehensive UK sCJD surveillance.
View Article and Find Full Text PDFGenome wide association study of clinical duration and age at onset of sporadic CJD.
PLoS One
July 2024
MRC Prion Unit at University College London (UCL), Institute of Prion Diseases, UCL, London, United Kingdom.
Article Synopsis
- Human prion diseases are unusual brain illnesses that can spread and cause quick changes in memory and thinking.
- The study looked at a specific type called sporadic Creutzfeldt-Jakob disease (sCJD), examining data from over 3,700 cases to understand how long the disease lasts and at what age it starts.
- Researchers found important genetic clues on chromosome 20 that can help understand how long people live with this disease, especially one specific genetic change that seems to have a big effect on survival time.
Updated global epidemiology atlas of human prion diseases.
Front Public Health
June 2024
National Key-Laboratory of Intelligent Tracking and Forecasting for Infectious Disease, National Health Commission Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Article Synopsis
- Human prion diseases (PrD) are fatal, transmissible neurodegenerative conditions, including CJD and vCJD, that have raised global health concerns, especially following the BSE outbreak.
- A comprehensive analysis from 1993 to 2020 of PrD case numbers was conducted using data from various international surveillance programs, revealing a growing trend in reported cases worldwide.
- The findings showed over 27,000 PrD cases, predominantly in higher-income countries, highlighting a lack of surveillance in many low-income nations, suggesting underreporting of these diseases globally.
Sporadic Creutzfeldt-Jakob disease in adults over 80 years: a 10-year review of United Kingdom surveillance.
Age Ageing
May 2024
The National CJD Research & Surveillance Unit, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.
Introduction: Sporadic Creutzfeldt-Jakob disease (sCJD) is a rapidly progressive neurodegenerative disease with public health implications. Mean age of onset is 68 years. Age-specific incidence declines after 80 years.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!